Autonomix reports results from exploratory subgroup analysis on PoC study

Autonomix (AMIX) Medical announced results from a post-hoc exploratory subgroup analysis of its previously reported first-in-human proof-of-concept study, PoC 1, evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with severe pancreatic cancer pain. Key Findings from the Subgroup Analysis: Consistent Improvements Across All Responders: Across all responding patients, average symptom scores improved by 14.53 points at 4-6 weeks and 26.07 points at 3-months, functionality increased by 8.15 and 25.56 points, and global quality of life improved by 8.33 and 18.06 points, respectively. All 3-month results exceeded the EORTC threshold for clinically meaningful change. Advanced Disease in Stage 4, Distant Metastatic Subgroup Shows Strong Response: Patients with Stage 4 pancreatic cancer, with both distant and regional metastases, achieved a 32.48 point symptom improvement and 11.85 point functional gain by 4-6 weeks, maintaining significant benefit at 3-months. Global quality of life scores improved by 19.44 points at 4-6 weeks and 25.00 points at 3-months. All timepoint results surpassed the EORTC’s threshold for clinically meaningful change. These findings confirm that ablation may provide durable, multidimensional relief even in metastatic and late-stage disease.